Sleep disturbance affects 39 to 47% of perimenopausal women and 35 to 60% of postmenopausal women, making it one of the most prevalent symptoms of the menopause transition. For many women, it is also the most debilitating, creating a cascade of consequences for mood, cognition, metabolic health, and physical performance that standard menopause consultations frequently address inadequately.
The Role of Oestrogen in Sleep Architecture
Oestrogen has direct effects on sleep architecture that are independent of its vasomotor effects. Oestrogen receptors are found in the raphe nuclei (serotonin production), the locus coeruleus (noradrenaline), and the suprachiasmatic nucleus (circadian clock). Declining oestrogen reduces serotonin synthesis, destabilises the circadian rhythm, reduces slow wave sleep percentage, and increases REM latency. These changes occur prior to and independently of hot flushes, meaning the sleep disruption associated with menopause has neurochemical and not just vasomotor causes.
Progesterone and Sleep Architecture
Progesterone and its metabolite allopregnanolone are potent GABA-A receptor positive allosteric modulators. The GABA system is the primary inhibitory neurotransmitter system in the brain and the target of benzodiazepine sleep medications. As progesterone declines in perimenopause, this endogenous sleep-promoting effect is lost, reducing sleep continuity and increasing sleep fragmentation independently of oestrogen changes.
Vasomotor Symptoms and Sleep Fragmentation
Hot flushes that occur during sleep (night sweats) produce arousal from sleep through thermosensory mechanisms. A 2005 study by Kravitz et al. in Sleep found that each objectively measured hot flush during sleep was associated with a significant cortical arousal. Women who experience frequent nocturnal vasomotor symptoms accumulate a substantial sleep debt over months and years, with consequent effects on metabolic health, mood, and cognitive function that are often attributed to ageing rather than correctly identified as sleep deprivation.
Evidence-Based Treatment Options
- HRT (hormone replacement therapy): consistently the most effective treatment for vasomotor-driven sleep disruption; also addresses the neurochemical sleep architecture changes through oestrogen and progesterone effects directly
- Cognitive behavioural therapy for insomnia (CBT-I): evidence for sleep improvement independent of and complementary to HRT; addresses the conditioned arousal and sleep restriction cycles that develop
- Melatonin: evidence for reduced sleep onset latency in menopausal women; 0.5 to 3mg taken 90 minutes before target sleep time
- Acupuncture: a 2019 RCT in Acupuncture in Medicine found 8 weeks of acupuncture significantly reduced insomnia severity in menopausal women
- Exercise: moderate intensity aerobic exercise 3 to 4 times per week reduces hot flush frequency and improves sleep quality
Sources
- Kravitz HM, et al. (2005). Sleep disturbance during the menopausal transition in a multi-ethnic community sample of women. Sleep, 28(11), 1449-1455.
- Baker FC, et al. (2018). Sleep problems during the menopausal transition: prevalence, impact, and management challenges. Nature and Science of Sleep, 10, 73-95.
- Polo-Kantola P. (2008). Dealing with menopausal sleep disturbances. Sleep Medicine Clinics, 3(1), 121-131.